The generic version of naloxone nasal spray, manufactured by Teva Pharmaceuticals, can be used in a community setting by individuals without medical training.
The approval, granted April 19, is part of the FDA’s effort to combat the nationwide opioid crisis.
The generic approval means there could soon be a generic alternative to Narcan, a widely used naloxone nasal spray sold by Emergent BioSolutions. However, it is unclear when the generic will be available as Teva is tied up in a legal battle with Narcan’s manufacturer.
Naloxone also can be administered intravenously. Generic versions of the injectable naloxone have been available for years in healthcare settings, but the nasal spray versions can be used by those without medical training, including civilians and first responders.
More articles on pharmacy:
Torrent Pharmaceuticals recalls 104 more lots of blood pressure drug
Civica Rx opens Utah headquarters
GlaxoSmithKline to lay off more than 240 workers in US, UK
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.